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Poster Session I S223million/kg single dose on day 2 after HSCT (n 5 18), or in repeat
doses of 1 or 5 M/kg on days 2, 9, 16, or 5 M/kg on days 2, 9, 16,
23 and 30 (n 5 18).
Table 1. MultiStem dose escalation strategy
Single dose Arm Repeat dose Arm (Days 2, 9, 16
(Day 2 after HSCT) or 2, 9, 16, 23 and 30 after HSCT)1 Million cells/kg 1 Million cells/kg  3 infusions
5 Million cells/kg 5 Million cells/kg  3 infusions
10 Million cells/kg 5 Million cells/kg  5 infusionsInfusional toxicity and RRTs are assessed as safety parameters for 30
days after the last MultiStem dose. Secondary evaluations include in-
cidences of Grade III/IV acute GVHD and infection and survival
through day 100. Dose assignment is guided by the Continual Reas-
sessment Method.
Results: Single dose arm; 15 patients were enrolled from 4 clinical
centers. Multistem was infused at 1, 5 and 10 million/kg. At this
point there has been no observation of infusional toxicity. Enroll-
ment is scheduled for completion by December 2010. Repeat dose
arm; appr. half of the multiple dose cohorts to be enrolled at this
time. Details of primary endpoints and preliminary results for sec-
ondary endpoints will be presented for the single dose arm.
Summary:This Phase 1 trial of the stromal stem cell productMulti-
Stem is focused on safety of repeated infusion during the first weeks
after HSCT, the critical period for engraftment with high risk for
first onset of aGVHD. This strategy will be exploited to determine
if MultiStem therapy can be harnessed for a potential new therapeu-
tic option for GVHD prophylaxis after HSCT.190
INTERCELLULAR CYTOSOLIC TRANSFER CORRELATESWITHMESENCHY-
MAL STROMAL CELL (MSC) RESCUE OF UMBILICAL CORD BLOOD (UCB)
CELL VIABILITY DURING EX VIVO UCB EXPANSION
Chu, P.P.Y.1,2, Bari, S.3,5, Fan, X.4, Gay, F.P.H.5, Ang, J.M.L.5,
Chiu, G.N.C.6, Chan, C.K.3, Hwang, W.Y.K.1,2,5 1Singapore General
Hospital, Singapore, Singapore; 2Singapore Cord Blood Bank, Singapore,
Singapore; 3National University of Singapore, Singapore, Singapore;
4Singapore General Hospital, Singapore, Singapore; 5Duke-NUS Grad-
uate Medical School, Singapore, Singapore; 6National University of Sin-
gapore, Singapore, Singapore
Mesenchymal Stromal Cell (MSC) co-culture enhances ex vivo ex-
pansion of hematopoietic stem and progenitor cells from thawed
Umbilical Cord Blood (UCB) without prior CD341/CD1331 cell
selection. We hypothesized that the superior ex vivo expansion is
due to reversal of UCB c apoptosis via intercellular cytosolic transfer
from the MSC to the UCB cells. MSC endogenously expressing
green fluorescent protein (GFP) or exogenously labeled with quan-
tumdots (QDs)were co-culturedwithUCBcells positive for a hema-
topoietic-specific CD45 marker. Cultured UCB cells without MSC
layer served as control. Annexin-V, JC-1 dye & caspase inhibitors
were used to investigatemitochondria-associated apoptosis pathway.
Flow cytometry & confocal imaging were used to detect for the
transfer of the GFP or QD in co-cultured UCB cells. Thawed
UCB cells had high percentage of early apoptotic cells (defined by
Annexin-V positivity) which progressed to dead cells (defined by
7AAD positivity). MSC co-culture resulted in reversal of Annexin-
V positivity and reached a maximum on day 3 (viability defined by
double negative staining for Annexin-V and 7AAD) (p\0.05). A sig-
nificant reduction in caspase 3/7, 8& 9 activity as well as preservation
of mitochondrial membrane potential were observed in the co-cul-
tured UCB cells (p\ 0.05). Upon co-culture with GFP-expressing
or QD-labelled MSC, unlabelled UCB cells were found positive
for these markers as early as 24 hours post co-culture. The number
of GFP & CD45 positive UCB cells increased over the first 3 days
of co-culturing, which correlated with viability increase. Direct con-
tact betweenMSC&UCB was necessary for the transfer, as negligi-
ble transfer was observed when the two populations were separated
by transwell inserts. Separation also showed a significant decrease
in viability. The UCB cells that tightly adhered to the MSC layer
exhibited optimal transfer & cell viability. DNA analysis of the via-
ble, GFP transfer-positive UCB cells, as determined by VariableNumber Tandem Repeat analysis ruled out the possibilities of
MSC trans-differentiation or MSC-UCB fusion. In addition, there
was statistical correlation between higher levels of cytosolic transfer
and enhanced UCB cell viability (p \ 0.0001). The above data
provides evidence that intercellular transfer of cytosolic materials
could be one novel mechanism preventing UCB cell death in MSC
co-culture.HISTOCOMPATIBILITY/ALTERNATIVE STEM
CELL SOURCES
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CLINICAL OUTCOMES OF HAPLOIDENTICAL DONOR COMPARED WITH
UNRELATED AND HLA-MATCHED RELATED DONOR HEMATOPOIETIC
STEM CELL TRANSPLANTATION FOR HEMATOLOGIC MALIGNANCIES
Luo, Y., Tan, Y., Hu, Y., Shi, J., Zheng, G., Zheng, W., Huang, H.
The First Affiliated Hospital, Zhejiang University School of Medicine,
Hangzhou, Zhejiang Province, China
Introduction: In clinical trials, an HLA-matched donor can be
found for about 50% to 60% of patients referred for HSCT which
greatly limits the application of allogeneic HSCT. Haploidentical
HSCTwould increase the availability of a donor to 100%.However,
haploidentical HSCTmay be associated with high risks of complica-
tions, such as graft rejection, severe GVHD and infection etc. Much
progress have been made due to advanced technologies applied in
haploidentical HSCT.
Materials and Methods: For haploidentical HSCT, conditioning
regimen consisted of Ara-C (4 g/m2/d) on day -10 and -9, Bu
(9.6mg/kg) on day -8, -7 and -6, Cy (1.8 g/m2/d) on day -5 and -4,
Me-CCNU (250 mg/kg) on day -3, and ATG (2.5 mg/kg/d) on
day -5 to -2. For unrelated and matched related HSCT, the condi-
tioning regimen consisted of Bu (0.8mg/kg -7d to -4d), Cy (60mg/
kg /d -3d and -2d). GVHD prophylaxis consisted of cyclosporine
A (CsA), mycophenolate mofetil (MMF), and short-termmethotrex-
ate while ATG were added in HLA-mismatched unrelated HSCT.
The data of 114 patients (38 with haploidentical donors, 35 with
HLA-matched related donors and 63 with unrelated donors) were
analyzed .
Results: The incidence of grade II–IV aGVHD was 36.8% in the
haploidentical group, 40.5% in the unrelated group and 22.9% in
the related matched group (p. 0.05 between haploidentical and un-
related, haloidentical and related matched group; p 5 0.0477 be-
tween urelated and related matched group). The 1 year OS were
68.4%, 78.4% and 91.3% in haploidentical, unrelated and relate
matched group respectively(p . 0.05 among the 3 groups). The 1
year TRM were 15.8%, 6.3% and 0% in haploidentical, unrelated
and related matched group respectively(p\0.0162 between haploi-
dentical and relatedmatched group; p. 0.05 between haploidentical
and unrelated, unrelated and matched related group).
Conclusions: There is a trend that survival in haploidentical group
and unrelated group is inferior to matched related group in patients
despite of statistical insignificance. AnHLA-matchedHSCT is com-
monly the preferred transplantation and donors fromHLA-matched
related siblings are usually the first choice. Haploidentical stem cell
transplantation is relatively safe and efficient for patients who do not
have HLA matched donors.192
A COST-BENEFIT ANALYSES COMPARING HAPLOIDENTICAL TRANSPLAN-
TATION WITH HLA MATCHED SIBLING AND URD IN HEMATOLOGICAL
MALIGNANCIES
Dong, L.1, Gao, Z.1, Zhang, M.-J.2, Tang, X.1, Liu, J.1, Yu, X.1,
Zhou, L.1, Xie, Y.1, Lu, D.1 1Fu Dan University, Shanghai Dao-Pei
Hospital, Shanghai, China; 2CIBMTR, Medical College of Wisconsin,
Milwaukee, WI
Background: Haploidentical (haplo) stem cell transplantation has
demonstrated intensive graft vs. leukemia effect and survival advan-
tage in patients with advanced leukemia. However, early virus reac-
tivation and acute GVHD may dramatically increase the cost of
treatment. Here we investigate the impact of donor types on clinical
outcomes and cost of treatment within 100 days of transplant.
Table 1. Cumulative incidence (CI) of neutrophil engraftment
andmedian day toANC>0.5 according to day 21 bonemarrow
S224 Poster Session IMethods:The study cohort consists of 117 consecutive patients (28
matched siblings, 25 unrelated and 64 haplo) with 115 leukemia, 1
SAA, and 1 NHL. The median age is 20 years (3-62). Conditioning
regimens: 1) Ara-C1BUCY (n5 14); 2) Ara-C1 BUFlu (n5 12). In
addition, Haplo and URD received either 3) Ara-C1 BUCY1ATG
(n 5 54) or, 4) Ara-C1BUFlu1ATG. (n 5 32) followed by unma-
nipulated G-CSF mobilized bone marrow and/or peripheral blood
(G-BMPBorG-PB). 5 patients used other regimen.GVHDprophy-
laxis: CSA, MMF and short-term MTX. Multiple linear regression
models were used for cost analysis. Variables considered were: trans-
plant type (Sibling vs. URD vs. Haplo), quality of life (QOL), D/R
sex match, patient age by decade, comorbidity, diagnoses, disease
status pre-transplant, conditioning regimen, graft type, MNC,
CD341cells, ANC and platelet engraftment, AGVHD and death.
Results: The median follow-up was 603 days (range 62 -1134).
Clinical outcomes are shown in the following table.
Table 1. Clinical Outcomes after transplantation
Sibling URD Haplo P composition and chimerism (n 5 56).P ValueTRM 100 day 0 (0-0)% 9 (2-24)% 5 (1-12)% 0.0634Day 21 BM CI Engraftment by BM Characteristic for CITRM 1 year 12 (3-27)% 15 (4-32)% 14 (7-24)% 0.9488Characteristic Sub-group (Day ANC $ 0.5) (RR , p value) ComparisonRelapse 100 day 11 (3-25)% 4 (0-16)% 3 (1-10)% 0.4640
Relapse 1 year 23 (10-40)% 19 (9-41)% 9 (3-18)% 0.2187% Total Myeloid <10% (n518) 10-50% (n518) >50% (n520) 0.017DFS 100 day 89 (70-96)% 87 (65-96)% 92 (82-97)% 0.7817Precursors 95% (27 days) 89% (27 days) 100%(22 days)DFS 1 year 65 (43-80)% 67 (37-84)% 77 (63-86)% 0.4721in Aspirate (RR 0.44, (RR 0.47, ReferenceSurvival 100 day 96 (77-99)% 91 (69-98)% 94 (84-98)% 0.7430(n556) p50.017) p50.028)Survival 1 year 84 (63-94)% 78 (49-91)% 83 (70-90)% 0.8780% Cellularity
in Core
(n556)
<5% (n521)
91% (30 days)
(RR 0.39,
p50.005)
5-9% (n515)
100% (27 days)
(RR 0.83,
p50.596)
>10% (n520)
95%(21 days)
Reference
0.005
% Total Donor
Chimerism
(n556)
<90% (n56)
67% (38 days)
(RR 0.16,
p50.001)
90-99% (n59)
100% (29 days)
(RR 0.42,
p50.026)
100% (n541)
98% (22 days)
Reference
0.001The overall median cost (range) within 100-day of transplant was
52,373USD (13,627 – 262,716). The mean cost (95% CI) of HLA
matched sibling, URD and haplo was 59,015 USD (45,537-
72,493), 61,970 USD (47,701-76,224) and 63,373 USD (54,463-
72,284) (P 5 0.8674), respectively. Multivariate cost analysis
indicated that QOL# 80, conditioning including Flu or Flu1ATG
and acute GVHD 2-4 correlated with increased cost.
Conclusion: These data suggest that transplant type (Sibling vs.
URD vs. Haplo) does not significantly effect on the clinical out-
comes and 100-day cost of transplantation. Future studies with
more patients and longer follow-up are warranted.193
TOTAL DONOR CHIMERISM IN THE DAY 21 BONE MARROW PREDICTS
SUSTAINED DONOR NEUTROPHIL ENGRAFTMENT FOLLOWING DOUBLE
UNIT CORD BLOOD TRANSPLANTATION (CBT)
Avery, S.1, Voss, M.H.1, Gonzales, A.M.1, Lubin, M.1, Castro-
Malaspina, H.1, Kernan, N.A.2, Scaradavou, A.2, Hedvat, C.3,
Stevens, C.E.1, Barker, J.N.1 1Memorial Sloan-Kettering Cancer Center;
2Memorial Sloan-Kettering Cancer Center; 3Memorial Sloan-Kettering
Cancer Center, New York, NY
Delayed or failed engraftment is a concern after CBT, even when
using double unit grafts. Therefore, we analyzed the ability of the day
21 bone marrow (BM) composition and percent donor chimerism to
predict sustained donor neutrophil engraftment in 56 recipients of
myeloablative double unit CBT. Patients (median age 29 years,
range 2-64) were transplanted for hematological malignancies, pre-
dominantly acute leukemia. Units had infused cell doses of 2.7 
107 TNC/kg/ 1.2  105 CD341 cells/kg for the larger unit, and
1.9  107 TNC/kg/ 0.7  105 CD341 cells/kg for the smaller
unit, with a donor-recipient HLA-match of 6/6 (n3), 5/6 (n59),
and 4/6 (n50). The cumulative incidence (CI) of neutrophil engraft-
ment was 95% (95% confidence interval: 89-100), with 47 patients
engrafting with 1 unit and 6 engrafting with 2. The percentage of to-
tal myeloid precursors in the day 21 BMaspirate (median 40%, range
0-87), and the percent cellularity in the day 21 BM biopsy (median
5%, range 0-80), were both associated with neutrophil engraftment
(Table 1). However, the most critical predictor of engraftment was
the percent total donor chimerism (unit#1 1 unit#2, median
100%, range 65-100), regardless if 1 or 2 units were present (Table
1). Sustained engraftment was seen in 98% of the 41 patients who
were 100% donor at day 21 with a median day to absolute neutrophil
count (ANC) $ 0.5 of 22 days. By contrast, only 87% of the 15 pa-
tients\ 100% total donor engrafted [median day to ANC $ 0.5 31days with a relative risk (RR) 0.3, p 5 0.001]. Patients who were
\90% donor had especially poor engraftment (Table 1). The asso-
ciation between total donor chimerism and engraftment was inde-
pendent of the percentage of myeloid precursors or BM cellularity.
In patients (n 5 37) without engraftment by day 21, a sub-group
of particular clinical concern, day 21 total donor chimerism was
also significantly associated with subsequent engraftment success
(p5 0.003). No patient demographic was associated with total donor
chimerism, and the only significant graft characteristic was the in-
fused CFU dose of the engrafting unit (p 5 0.002). These findings
demonstrate the critical importance of the day 21 BM total donor
chimerism and are of practical significance in the care of double
unit CBT recipients. Further, they give interesting insights into dou-
ble unit biology and suggest that the hematopoietic potential of the
engrafting unit underlies the ability to generate complete donor chi-
merism.194
THE T-CELL EPITOPE (TCE) ALGORITHM FOR CLASSIFYING HLA-DPB1
MISMATCHES DOES NOT PREDICT CLINICAL OUTCOMES IN HSCT
Askar, M., Flanagan, P., Rybicki, L., Kalaycio, M., Pohlman, B.,
Andresen, S., Dean, R., Duong, H., Copelan, E., Bolwell, B., Sobecks, R.
Cleveland Clinic
A number of reports suggested the relevance of HLA-DPB1
matching for the outcomes of allogeneic hematopoietic stem cell
transplantation (HSCT). An algorithm for determining DPB1 mis-
match permissiveness based on T-Cell Epitopes (TCE) has been
proposed (Zino et al, Blood 2004). According to this algorithm, all
DPB1 alleles are categorized in 3 (TCE3) or 4 (TCE4) groups based
on antigenicity. Accordingly DPB1 mismatches are classified as
permissive; non-permissive in GvHD; or non-permissive in HvG
direction.
Objective: To determine whether TCE classification is associated
with HSCT outcomes. The outcomes considered in this analysis are
failure to engraft, acute GvHD, chronic GvHD, and overall survival.
Methods:We analyzed 144 unrelated donor ($ 7/8 allelematches at
A, B, C, DRB1) allogeneic transplants performed in our center be-
tween 1999-2009. HLA-DPB1 mismatches were assessed using
both TCE3 and TCE4 versions of the algorithm. Recursive parti-
tioning analysis with a log-rank splitting method was used to catego-
rize TCE variables into groups that best predict each outcome. Cox
proportional hazards analysis was used to identify prognostic factors
for each outcome.
Results:Graft failure was significantly highest among recipient with
permissive DPB1 mismatches (AHR 9.87, 95% CI 1.21-80.3, P 5
0.03) compared to recipients of zero mismatched, GvHD non-per-
missive, and HvG nonpermissive DPB1 mismatched donors. Acute
GvHD was significantly higher in all DPB1 mismatches regardless
of TCE classification (AHR 1.93, 95%CI 1.11-3.34, P5 0.02) com-
pared zeroDPB1mismatch. There was no significant association be-
tween TCE classification and chronic GvHD, or overall survival.
